Replimune Group, Inc. (REPL): Net Income
-$313.94M
Year ended 2026-03-31
-$297.01M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | -$313.94M | n/m | 2026-06-29, From 2025-04-01 |
| 2025-03-31 | -$247.30M | n/m | 2026-06-29, From 2024-04-01 |
| 2024-03-31 | -$215.79M | n/m | 2025-05-22, From 2023-04-01 |
| 2023-03-31 | -$174.28M | n/m | 2024-05-16, From 2022-04-01 |
| 2022-03-31 | -$118.04M | n/m | 2023-05-18, From 2021-04-01 |
| 2021-03-31 | -$80.87M | n/m | 2022-05-19, From 2020-04-01 |
| 2020-03-31 | -$52.62M | n/m | 2021-05-20, From 2019-04-01 |
| 2019-03-31 | -$30.83M | n/m | 2020-06-03, From 2018-04-01 |
| 2018-03-31 | -$19.70M | n/m | 2020-06-03, From 2017-04-01 |
| 2017-03-31 | -$7.70M | n/a | 2019-06-28, From 2016-04-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Replimune Group, Inc. (REPL) | 2026-03-31 | -$313.94M | n/m |
| Prokidney Corp. (PROK) | 2025-12-31 | -$151.61M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | -$201.14M | n/m |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | -$109.00M | n/m |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | -$136.31M | n/m |
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | -$229.97M | n/m |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | -$104.99M | n/m |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | -$82.13M | n/m |
| Scilex Holding Co (SCLX) | 2025-12-31 | -$374.05M | n/m |
Compare REPL, PROK, PRME, TSHA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗